News

Scientists have developed a system that can generate human antibodies against various antigens faster than existing methods.

With doctors and researchers around the world searching for effective treatments for COVID-19, many drugs approved to treat other diseases are being used in hopes that they’ll be effective against the virus. Researchers have cataloged every use documented in medical literature so far.

Inhibiting a molecule hijacked by tumor cells to suppress the immune system shrank tumors in cell and mouse models.

Researchers have identified two classes of compounds that prevent most of the effects of interferon-α (IFNα) on human beta cells, paving the way for potential future clinical trials of treatments for Type 1 diabetes (T1D).

Following on from remdesivir’s promising results from previous studies, a new trial is now investigating remdesivir in combination with baricitinib or placebo as a treatment for COVID-19, in a double-blind, randomized trial.

Researchers have now succeeded in visualizing spatial changes within tumors using optoacoustics. This method could be helpful for the future development of new anticancer drugs.

In vitro studies have uncovered new insights that could help increase the effectiveness of the most common current treatments with the addition of lumefantrine, an FDA-approved drug used to treat malaria.

The anti-viral drug remdesivir will be made available to select NHS patients meeting certain clinical criteria to support their recovery from COVID-19.

Patients with metastatic pancreatic cancer who had germline or somatic mutations in DNA repair genes had better clinical outcomes after platinum-based chemotherapy, compared with patients that did not have these mutations, according to a new study.

Johns Hopkins Medicine researchers report that although some progress has been made, women and older adults are still underrepresented in lipid lowering therapy trials compared with their disease burden.